Chinese medicine NeuroAiD efficacy stroke recovery - Extension study (CHIMES-E study): An observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery

Cerebrovascular Diseases

Volumn 35, Issue SUPPL.1, 2013, Pages 18-22

  Venketasubramanian, N ^a,c   Young, Sherry ^d   Tay, San San ^d   Chang, Hui Meng ^e   Umapathi, T ^f   Chan, Bernard ^a   De Silva, Asita ^h   Wong, Lawrence ⁱ   Navarro, Jose ^j   Zhao, Yu Dong ^g   Tan, Say Beng ^g   Chen, Christopher ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c RAFFLES HOSPITAL   (Singapore)

^d CHANGI GENERAL HOSPITAL   (Singapore)

^e NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^f TAN TOCK SENG HOSPITAL   (Singapore)

^g SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^h UNIVERSITY OF KELANIYA   (Sri Lanka)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

more..

Author keywords

NeuroAiD; Recovery; Stroke; Traditional Chinese medicine

Indexed keywords

MLC 601; NEUROAID; NEUROPROTECTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG; CHINESE DRUG;

ADULT; ARTICLE; BARTHEL INDEX; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHINESE MEDICINE; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY (TOPIC); NEUROIMAGING; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RECURRENT DISEASE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; STROKE PATIENT;

CEREBRAL INFARCTION; DATA INTERPRETATION, STATISTICAL; DRUGS, CHINESE HERBAL; ENDPOINT DETERMINATION; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGIC EXAMINATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RESEARCH DESIGN; STROKE; TELEPHONE; TREATMENT OUTCOME;

EID: 84875999529     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000346233     Document Type: Article

References (30)

1. Appelros P, Nydevik I, Viitanen M: Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003; 34:122-126.
2. Hankey GJ: Long-term outcome after isch-aemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16(suppl 1):14-19.
3. Fransen M, Anderson C, Chalmers J, Chapman N, Davis S, MacMahon S, Neal B, Sega R, Terent A, Tzourio C, Woodward M, PROGRESS: Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6,105 patients with cerebro-vascular disease: a randomized controlled trial. Stroke 2003; 34:2333-2338.
4. Stroke Unit Trialists' Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007:CD000197.
5. National Institute of Neurological Disorders and Stroke rt-PA Study Group: Tissue plas-minogen activator for the treatment of acute ischaemic stroke. New Engl J Med 1995; 333: 1581-1587.
6. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
7. Kwiatkowski TG, Libman RB, Frankel M, Til-ley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340:1781-1787.
8. Mold F, Wolfe C, McKevitt C: Falling through the net of stroke care. Health Soc Care Community 2006; 14:349-356.
9. Eissa A, Krass I, Bajorek BV: Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). J Clin Pharm Ther 2012; 37:620-629.
10. Ginsberg MD: Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009; 40(suppl 3):S111-S114.
11. Paolucci S, De Angelis D: New developments on drug treatment rehabilitation. Clin Exp Hypertens 2006; 28:345-348.
12. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I: Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10:123-130.
13. Martinsson L, Eksborg S: Drugs for stroke recovery: the example of amphetamines. Drugs Aging 2004; 21:67-79.
14. Ramic M, Emerick AJ, Bollnow MR, O'Brien TE, Tsai SY, Kartje GL: Axonal plasticity is associated with motor recovery following amphetamine treatment combined with rehabilitation after brain injury in the adult rat. Brain Res 2006; 1111:176-186.
15. Stroemer RP, Kent TA, Hulsebosch CE: Enhanced neocortical neural sprouting, synap-togenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke 1998; 29:2381-2393.
16. Sprigg N, Bath PM: Speeding stroke recovery? A systematic review of amphetamine after stroke. J Neurol Sci 2009; 285:3-9.
17. Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, Lai J, Unwin DH: A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001; 32:2093-2098.
18. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R: Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995; 26: 2254-2259.
19. Pandian JD, Liu M, Misbach J, Venketasubra-manian N: Alternative therapies for stroke treatment in Asia. Int J Stroke 2011; 6:541-543.
20. Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, Chan E, Bousser MG, Xuemin S: Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke 2009; 40: 859-863.
21. Siow CH: Neuroaid in stroke recovery. Eur Neurol 2008; 60:264-266.
22. Kong KH, Wee SK, Ng CY, Chua K, Chan KF, Venketasubramanian N, Chen C: A doubleblind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine Neu-roAiD (MLC 601) in enhancing recovery after stroke (TIERS). Cerebrovasc Dis 2009; 28: 514-521.
23. Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, Shahbegi S, Pakdaman H, Tabasi M, Tabata-bae AL, Nourian A: Safety and Efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. Stroke Res Treat 2011; 2011:721613.
24. Gan R, Lambert C, Lianting J, Chan ES, Ven-ketasubramanian N, Chen C, Chan BP, Sama-ma MM, Bousser MG: Danqi Piantan Jia-onang does not modify hemostasis, hematol-ogy, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis 2008; 25: 450-456.
25. Young SH, Zhao Y, Koh A, Singh R, Chan BP, Chang HM, Venketasubramanian N, Chen C; CHIMES Investigators. Safety profile of MLC601 (Neuroaid) in acute ischemic stroke patients: a Singaporean substudy of the Chinese Medicine Neuroaid Efficacy on Stroke recovery study. Cerebrovasc Dis 2010; 30:1-6.
26. TM (MLC601) on cerebral blood flow velocity in subjects' post-brain infarct in the middle cerebral artery territory. Eur J Intern Med 2011; 22:509-513.
27. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, Onteniente B, Lazdunski M: Neuroprotective and neu-roproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 2010; 58:987-1001.
28. Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, Lazdunski M, Heurteaux C: MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology 2011; 61:622-6231.
29. Moha Ou Maati H, Borsotto M, Chatelain F, Widmann C, Lazdunski M, Heurteaux C: Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation. Neuro-pharmacology 2012; 63:692-700.
30. Venketasubramanian N, Chen CL, Gan RN, Chan BP, Chang HM, Tan SB, Picard D, Na-varro JC, Baroque AC 2nd, Poungvarin N, Donnan GA, Bousser MG, CHIMES Investigators: A double-blind, placebo-controlled, randomized, multicenter study to investigate Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES Study). Int J Stroke 2009; 4:54-60.